Daily Stock Analysis, CDTX, Cidara Therapeutics Inc, priceseries

Cidara Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
7.75
Close
7.85
High
7.88
Low
7.70
Previous Close
7.60
Daily Price Gain
0.25
YTD High
11.75
YTD High Date
Feb 17, 2017
YTD Low
5.60
YTD Low Date
Aug 16, 2017
YTD Price Change
-2.30
YTD Gain
-22.66%
52 Week High
11.75
52 Week High Date
Feb 17, 2017
52 Week Low
5.60
52 Week Low Date
Aug 16, 2017
52 Week Price Change
-3.20
52 Week Gain
-28.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 23. 2015
14.59
Dec 11. 2015
16.06
13 Trading Days
10.06%
Link
LONG
Mar 29. 2016
10.88
Apr 18. 2016
13.81
14 Trading Days
26.89%
Link
LONG
Nov 9. 2016
10.15
Nov 21. 2016
10.87
8 Trading Days
7.10%
Link
LONG
Sep 20. 2017
6.95
Oct 6. 2017
7.69
12 Trading Days
10.66%
Link
Company Information
Stock Symbol
CDTX
Exchange
NasdaqGM
Company URL
http://http://www.cidara.com
Company Phone
858-752-6170
CEO
Jeffrey L. Stein
Headquarters
California
Business Address
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001610618
About

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases.

Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease, as well as engages in evaluating Cloudbreak candidates for the treatment of invasive fungal infections, including aspergillosis, an infection caused by the fungal pathogen. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.